Quarterly ResultMay 8, 2026, 04:38 PM
Femasys Q1 Net Income $846K; Sales Up 24.5% to $424K
AI Summary
Femasys Inc. announced its financial results for the first quarter ended March 31, 2026, reporting a significant turnaround with a net income of $846,100, compared to a net loss of $5.9 million in the prior year. Sales increased by 24.5% to $424,889, primarily driven by FemBloc sales, while R&D expenses decreased by 55.9%. The company also provided a corporate update highlighting the commercial adoption of FemaSeed Complete, initiation of the FemBloc FINALE pivotal clinical trial, and expansion into international markets through strategic partnerships.
Key Highlights
- Sales increased by 24.5% to $424,889 in Q1 2026 from $341,264 in Q1 2025.
- Reported net income of $846,100 in Q1 2026, compared to a net loss of $5,896,839 in Q1 2025.
- Research and development expenses decreased by 55.9% to $1,309,401 in Q1 2026.
- Cash and cash equivalents were approximately $5.4 million as of March 31, 2026.
- Advanced initial commercial adoption and launched FemaSeed Complete at ACOG 2026.
- Initiated patient enrollment in the FINALE pivotal clinical trial for FemBloc®.
- Established strategic partnerships in Israel and Switzerland for fertility portfolio commercialization.
- Received AMA CPT Editorial Panel approval of a new Category III CPT code for FemaSeed.
Price Impact
More from FEMY